UNDERSTANDING THE MOLECULAR BASIS OF JN.1

Authors

  • Dr. Raghavendra Rao M. V. Scientist-Emeritus, and Director Research, Apollo Institute of Medical Sciences and Research, Jubilee Hills, Hyderabad, Telangana, India
  • Dr. Vijaykumar Chennamchetty Associate Professor, Department of Pulmonary Medicine, Apollo Institute of Medical Sciences Education and Research, Hyderabad- (TS)
  • Dr. Pavani G. Department of Clinical Microbiology, Apollo Institute of Medical Sciences and Research, Hyderabad, TS, India
  • Dr. Manick Dassa Professor and Head, Department of Clinical Microbiology, Apollo Institute of Medical Sciences and Research, Hyderabad, TS, India
  • Dr. Srilatha Basetty Department of Biochemistry, Dr. Patnam Mahender Reddy Institute of Medical Sciences, Chevella, Hyderabad, TS, India
  • Dr. Rajkumar Kudari Professor, Hindu College of Pharmacy, Guntur, AP, India
  • Dr. Mahendra Kumar Verma Assistant Professor, Basic Medical Sciences, American University School of Medicine, Aruba
  • Dr. Abdur Rahman Consultant Biochemist, Vijaya Diagnostic Center, Tolichowki, Hyderabad, TS, Hyderabad, India
  • Dr. P. Jaganmohan Rao Director, Nuklein Biotec, Haranathapuram, Nellore, AP, India

DOI:

https://doi.org/10.21276/IERJ24815318066840

Keywords:

Indian SARS-CoV-2 Genomic Consortium (INSACOG), Pirola Variant (BA 2.86)

Abstract

COVID-19 JN.1,subvariant, was initially identified in Luxembourg and is believed to have a connection to the Pirola variant (BA 2.86), which is considered a derivative of the Omicron subvariant.The new Omicron variant of SARS-cov-2 speeding around the world may bring another wave of chaos. It is like walking on a tightrope. The earth is brimming with viruses. The lungs are the paramount respiratory organs. Covid 19 sub variant JN.1 detected in 79 years old Kerala woman.It has been detected in Kerala amid surveillance led by Indian SARS-CoV-2 Genomic Consortium (INSACOG).Originally part of lineage BA.2.86, JN.1 is now recognized as a distinct variant of interest by the WHO. Reassuringly, WHO states that current vaccines remain effective against severe disease and death caused by JN.1 and other circulating COVID-19 variants. In early December, the CDC, reported that the JN.1 subvariant constitutes an estimated 15% to 29% of cases in the United States, as per the agency's most recent projections. According to the CDC, JN.1 was initially identified in the United States in September. Additionally, China reported seven infections of the COVID subvariant. 

References

I. 1.Yang S ,Yu Y ,Jian F et al.Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect Dis. 2023; 23: e457-e459

II. Wannigama DL ,Amarasiri M ,Phattharapornjaroen P ,et al. Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand. Lancet Infect Dis. 2023; 23: e464-e466

III. Wang Q ,Guo Y ,Liu L et al.Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.Nature. 2023; (published online Oct 23.)https://doi.org/10.1038/s41586-023-06750-w

IV. Cao Y ,Song W ,Wang L ,et al. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.Cell Host Microbe. 2022; 30: 1527-1539

V. Cao Y et al.Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD binding domain evolution.Nature. 2023; 614: 521-529

VI. Yue C ,Song W ,Wang L .et al.ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.Lancet Infect Dis. 2023; 23: 278-280

VII. Wang Q ,Li Z ,Guo Y ,et al. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2.Science. 2023; 26108254

VIII. Mahase E Covid-19: New “Pirola” variant BA.2.86 continues to spread in UK and US. BMJ2023;382:p2097. doi:10.1136/bmj.p2097 pmid:37704230

IX. Vinall F, Nirappil F. New coronavirus variant JN.1 is spreading fast. Here’s what to know. Washington Post 2023 Dec,20. https://www.washingtonpost.com/wellness/2023/12/20/new-covid-variant-jn1-symptoms

X. Roxby P. JN.1 covid variant: WHO charts its rapid global spread. BBC News 2023 Dec 20. https://www.bbc.co.uk/news/health-67772390

XI. Roy S. WHO says JN.1 covid strain a “variant of interest,” poses low risk. Reuters. 19 Dec 2023. https://www.reuters.com/business/healthcare-pharmaceuticals/who-classifies-jn1-covid-19-variant-interest-2023-12-19/

XII. Goodman B. Coronavirus subvariant JN.1 growing fast in US, already dominant in the northeast. CNN Health 2023 Dec 19. https://edition.cnn.com/2023/12/19/health/what-to-know-about-jn-1/index.html

XIII. Nasserie T, Hittle M, Goodman SNAssessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw Open2021;4:e2111417. doi:10.1001/jamanetworkopen.2021.11417 pmid:34037731

XIV. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med2021;27:601-15. doi:10.1038/s41591-021-01283-z pmid:33753937

XV. Ayoubkhani D, Khunti K, Nafilyan V, et al.Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ2021;372:n693. doi:10.1136/bmj.n693 pmid:33789877

XVI. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun2022;103:154-62. doi:10.1016/j.bbi.2022.04.013 pmid:35447302

XVII. Sivan M, Parkin A, Makower S, Greenwood DC Post-COVID syndrome symptoms, functional disability, and clinical severity phenotypes in hospitalized and nonhospitalized individuals: A cross-sectional evaluation from a community COVID rehabilitation service. J Med Virol2022;94:1419-27. doi:10.1002/jmv.27456 pmid:34783

XVIII. Blomberg B, Cox RJ, Langeland N,Long COVID: A growing problem in need of intervention. Cell Rep Med2022;3:100552. doi:10.1016/j.xcrm.2022.100552 pmid:35474749

XIX. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.

XX. Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions. 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html

XXI. Uriu K, Ito J, Kosugi Y, et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect Dis 2023; 23(11): e460–e1.

XXII. Sheward DJ, Yang Y, Westerberg M, et al. Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses. Lancet Infect Dis 2023; 23(11): e462–e3.

XXIII. Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell 2022; 185(12): 2103–15.e19

XXIV. Anuradha Mascarenhas,The Indian express,Pune December 22, 2023

XXV. Update on SARS-CoV-2 Variant JN.1 Being Tracked by CDC,December 8, 2023,

XXVI. Source:https://theprint.in/health/who-says-jn-1-covid-strain-a-variant-of-interest-poses-low-risk/1893262

XXVII. Ankita Upadhyay, The Indian express,Delhhi | December 22, 2023 10:57 IST

XXVIII. BINDU SHAJAN PERAPPADAN,The Hindu,December 24, 2023 NEW DELHI

Additional Files

Published

15-01-2024

How to Cite

Dr. Raghavendra Rao M. V., Dr. Vijaykumar Chennamchetty, Dr. Pavani G., Dr. Manick Dass, Dr. Srilatha Basetty, Dr. Rajkumar Kudari, Dr. Mahendra Kumar Verma, Dr. Abdur Rahman, & Dr. P. Jaganmohan Rao. (2024). UNDERSTANDING THE MOLECULAR BASIS OF JN.1. International Education and Research Journal (IERJ), 10(1). https://doi.org/10.21276/IERJ24815318066840

Most read articles by the same author(s)